SLC25A26-mediated SAM compartmentalization coordinates translation and bioenergetics during cardiac hypertrophy

Ningning Guo,Jian Lv,Yu Fang,Qiuxiao Guo,Jiajie Li,Junmei Wang,Xiao Ma,Qingqing Yan,Fuqing Jiang,Shuiyun Wang,Li Wang,Zhihua Wang

DOI: https://doi.org/10.1101/2024.07.30.24311193

2024-08-02

Abstract:BACKGROUND: The heart undergoes hypertrophy as a compensatory mechanism to cope with increased hemodynamic stress, and it can transition into a primary driver of heart failure. Pathological cardiac hypertrophy is characterized by excess protein synthesis. Protein translation is an energy-intensive process that necessitates an inherent mechanism to flexibly fine-tune intracellular bioenergetics according to the translation status; however, such a molecular link remains lacking. METHODS: Slc25a26 knockout and cardiac-specific conditional knockout mouse models were generated to explore its function in vivo. Reconstructed adeno-associated virus was used to overexpress Slc25a26 in vivo. Cardiac hypertrophy was established by transaortic constriction (TAC) surgery. Neonatal rat ventricular myocytes were isolated and cultured to evaluate the role of SLC25A26 in cardiomyocyte growth and mitochondrial biology in vitro. RNA sequencing was conducted to explore the regulatory mechanism by SLC25A26. m1A-modified tRNAs were profiled by RNA immuno-precipitation sequencing. Label-free proteomics was performed to profile the nascent peptides affected by S-adenosylmethionine (SAM). RESULTS: We show that cardiomyocytes are among the top cell types expressing the SAM transporter SLC25A26, which maintains low-level cytoplasmic SAM in the heart. SAM biosynthesis is activated during cardiac hypertrophy, and feedforwardly mobilizes the mitochondrial translocation of SLC25A26 to shuttle excessive SAM into mitochondria. Systemic deletion of Slc25a26 causes embryonic lethality. Cardiac-specific deletion of Slc25a26 causes spontaneous heart failure and exacerbates cardiac hypertrophy induced by transaortic constriction. SLC25A26 overexpression, both before or after TAC surgery, rescues the hypertrophic pathologies and protects from heart failure. Mechanistically, SLC25A26 maintains low-level cytoplasmic SAM to restrict tRNA m1A modifications, particularly at A58 and A75, therefore decelerating translation initiation and modulating tRNA usage. Simultaneously, SLC25A26-mediated SAM accumulation in mitochondria maintains mitochondrial fitness for optimal energy production. CONCLUSIONS: These findings reveal a previously unrecognized role of SLC25A26-mediated SAM compartmentalization in synchronizing translation and bioenergetics. Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac hypertrophy and heart failure.

Cardiovascular Medicine

What problem does this paper attempt to address?

### What problems does this paper attempt to solve?

This paper aims to reveal how S - adenosylmethionine (SAM) coordinates the relationship between translation and bioenergetic metabolism through SLC25A26 - mediated intracellular distribution during cardiac hypertrophy. Specifically, the researchers focus on the following key issues:

1. **Molecular mechanisms of cardiac hypertrophy**: Cardiac hypertrophy is a compensatory mechanism of the heart in response to increased hemodynamic pressure, but long - term pressure may lead to heart failure. One of the characteristics of pathological cardiac hypertrophy is excessive increase in protein synthesis. However, the regulatory mechanism of this protein synthesis is still unclear at present.

2. **Coordination of translation and bioenergetic metabolism**: Translation is a highly energy - consuming process, and an internal mechanism is required to flexibly adjust intracellular bioenergetic metabolism to adapt to the translation state. The researchers hope to find this molecular link.

3. **Function of SLC25A26**: SLC25A26 is a SAM transporter, mainly expressed in cardiomyocytes. The researchers hope to explore its role in cardiac hypertrophy by knocking out or over - expressing SLC25A26.

4. **Intracellular distribution of SAM and its influence**: The researchers found that during cardiac hypertrophy, SAM biosynthesis is activated, and SLC25A26 transports the excess SAM from the cytoplasm to the mitochondria. They hope to reveal how the intracellular distribution of SAM affects translation and mitochondrial function by studying this process.

### Main conclusions

Through a series of experiments, the researchers reached the following main conclusions:

- SLC25A26 maintains the normal function and energy production of mitochondria during cardiac hypertrophy by transporting the excess SAM to the mitochondria.
- SLC25A26 limits the SAM level in the cytoplasm, thereby inhibiting m1A modification of tRNA (especially at A58 and A75 sites), slowing down translation initiation and regulating tRNA usage.
- Cardiac - specific knockout of Slc25a26 leads to spontaneous heart failure and aggravates cardiac hypertrophy induced by aortic constriction (TAC).
- Over - expression of SLC25A26 can rescue the pathological changes caused by cardiac hypertrophy and protect the heart from heart failure.

These findings reveal the importance of SLC25A26 - mediated SAM intracellular distribution for coordinating translation and bioenergetic metabolism, and provide new potential targets for the treatment of cardiac hypertrophy and heart failure.